The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Global Preventive Vaccines Market, 2020-2030

  • Lowest Price Guaranteed From USD 4,899

  • Published
    April 2020

  • Pages
    248

  • View Count
    1677

Example Insights

Global-Preventive-Vaccines-Market-Context Global-Preventive-Vaccines-Market-List-of-clinical-stage 	Global-Preventive-Vaccines-Market-Stages-of-development
Global-Preventive-Vaccines-Market-Company-competitiveness-analysis Global-Preventive-Vaccines-Market-Funding-and-investment-analysis Global-Preventive-Vaccines-Market-Geographical-distribution
Global-Preventive-Vaccines-Market-List-of-vaccines-contract Global-Preventive-Vaccines-Market-Futuer-forecast  

 

Overview

Vaccines are versatile preventive formulations that have, so far, enabled the global eradication of smallpox (1980) and polio (2015), which are both debilitating viral diseases. According to the WHO, currently, global vaccination coverage is nearly 85%. This is believed to be responsible for preventing close to three million deaths, which would have otherwise been caused by infectious diseases, such as chickenpox, diphtheria, measles, pneumonia, tetanus, and tuberculosis. In fact, recent immunization records indicate that more than 115 million children are immunized against diphtheria, tetanus and pertussis annually. However, vaccine development, especially against newly identified pathogens, is a challenging and time consuming process. For instance, authorities claim that although there are many initiatives investigating vaccines against the recently identified SARS-CoV-2 coronavirus strain, a viable vaccine is still a year away. Other barriers to vaccine development include lack of pathogen specific information, inadequate immunity (conferred by certain types of vaccines), existence of multiple pathogenic strains, and reversion potential (a phenomenon where a weakened pathogen intended for use as a vaccine, reverts to its infectious phenotype). 

Despite the success achieved, so far, through vaccination, it is estimated that over 1.5 million children, under the age of five, die of vaccine-preventable diseases, every year. This is largely attributed to storage (loss of efficacy upon prolonged storage) and logistics-related (cold chain requirement) complexities, which impact adequate distribution and transportation of such medications to remote areas. Given the rate at which the global population is growing, the demand for vaccines is anticipated to increase significantly. In this regard, significant strides have been made in improving existing vaccine formulations, mostly focused on enhancing stability. Recent technical advances, especially in the field of biotechnology, have heralded a new era in immunogen design for vaccine development. Moreover, many developers claim to be working on next generation preventive vaccine candidates, such as recombinant vaccines, viral vector-based vaccines and DNA vaccines, which have been demonstrated to elicit powerful immune responses, resulting in the development of immunologic memory. Further, a variety of adjuvants (substances with the innate potential to augment an immune response) have been discovered and are now available for the development of more versatile vaccine formulations. Several regional government bodies and private investors are actively financing stakeholders in this industry. Given that in the recent past there has been a marked rise in new entrants in this field, we anticipate this market to witness substantial growth in the coming years.

Scope of the Report

The ‘Global Preventive Vaccines Market, 2020-2030’ report features an extensive study of the current market landscape and future opportunities associated with the preventive vaccine domain. The study also features a detailed analysis of the key drivers and trends related to this evolving segment of the pharmaceutical industry. Amongst other elements, the report includes:

  • A detailed assessment of the current market landscape, including information on type of developer (industry, non-industry, industry / non-industry), phase of development (phase I, phase I/II, phase II, phase II/III, phase III and preregistration) of lead candidates, route of administration (intramuscular, intranasal, oral, intradermal, subcutaneous, intravenous and others), type of vaccine API (live, attenuated vaccine, recombinant vaccine, conjugate vaccine, inactivated vaccine, DNA vaccine, peptide vaccine, subunit vaccine, mRNA vaccine, toxoid vaccine and others), dosage form (ready to use liquid, lyophilized powder, nasal spray, capsule and tablet), dosage (single dose, 2 doses, 3 doses, 4 doses, 5 doses and 6 doses), target disease indication and target patient population (children, adults and seniors).
  • A competitiveness analysis of preventive vaccine developers, taking into consideration supplier strength (based on company size and its experience in this field) and pipeline strength (based on the number of clinical-stage vaccine candidates, highest phase of development, number of compatible routes of administration, number of indications evaluated, number of APIs evaluated and target patient population).
  • Elaborate profiles of the key preventive vaccine developers (shortlisted based on a proprietary criterion) across North America, Europe and Asia Pacific. Each profile includes a brief overview of the company, its year of establishment, location of headquarters, number of employees and financial information (if available). In addition to this, the profile includes information on the various clinical-stage vaccine candidates developed by the company. Further, we have provided the recent developments of the company and an informed future outlook.
  • A detailed analysis of more than 1,400 completed, ongoing and planned clinical studies of preventive vaccines, highlighting prevalent trends across various relevant parameters, such as trial registration year, phase of development, trial recruitment status, study design, trial focus area, type of preventive vaccine (based on pathogen), target disease indication(s),  type of sponsor / collaborator, leading industry sponsors / collaborators (in terms of number of trials conducted), enrolled patients population and regional distribution.
  • An overview of the ongoing vaccine development initiatives for complex conditions, such as COVID-19, ebola virus disease, HIV/AIDS, malaria and zika virus infection, including information on disease, its global burden, current treatment landscape and preventive vaccine research landscape. Further, we have provided the information on investments made and recent developments in the domain.
  • An analysis of the investments made in this domain, during the period between 2015 and 2020 (till March), including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of development in companies that are engaged in developing preventive vaccines. 
  • A case study on contract manufacturing landscape for vaccines, featuring a comprehensive list of active CMOs and analyses based on a number of parameters, such as year of establishment, company size, scale of operation (preclinical, clinical and commercial), geographical location, number of vaccine manufacturing facilities, types of services offered (cell / virus banking, analytical development / testing, formulation, process development, fill / finish and regulatory filings), type of expression systems used for vaccine production (mammalian, microbial and others) and type of vaccine manufactured.

One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities for preventive vaccines over the coming decade. Based on several parameters, such as target consumer segments, region specific adoption rates and expected prices of such products, we have provided an informed estimate on the likely evolution of the market over the period 2020-2030. The report also provides details on the likely distribution of the current and forecasted opportunity across [A] route of administration (intramuscular, subcutaneous, oral, intranasal, intradermal and others), [B] type of vaccine (pneumococcal conjugate vaccine, human papilloma virus vaccine, influenza vaccine, rotavirus vaccine, varicella vaccine, DTP-HepB-Hib vaccine, meningococcal group A, C, Y and W-135 vaccine and others), [C] type of vaccine API (live attenuated vaccine, inactivated vaccine, conjugate vaccine, subunit vaccine, toxoid vaccine and others), [D] target patient population (pediatric and adults) and [E] key geographical regions, covering North America (the US, Mexico and Canada), Europe (Spain, the UK, Italy, France, Germany and rest of Europe), Asia Pacific (India, China, Australia and rest of Asia Pacific), and rest of the world. In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth. 

Contents

Chapter Outlines

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the preventive vaccines market and its likely evolution in the short-mid term and long term.

Chapter 3 provides a general introduction to vaccines, as well as their classification based on the type of active ingredient. The chapter also includes an overview of the various expression systems that have been / are being used in the development and production of vaccines. Along with these, later sections highlight a discussion on the various routes of vaccine administration. It also features a brief overview of clinical development and approval processes for vaccines. The chapter ends with a discussion on the challenges and growth drivers that are likely to impact the evolution of the vaccines market in the comping years. 

Chapter 4 provides a detailed assessment of the current market landscape of over 200 preventive vaccines that are currently being evaluated in different stages of development. It features a comprehensive analysis of pipeline molecules based on a number of parameters, such as type of developer (industry, non-industry, industry / non-industry), phase of development (phase I, phase I/II, phase II, phase II/III, phase III and preregistration) of lead candidates, route of administration (intramuscular, intranasal, oral, intradermal, subcutaneous, intravenous and others), type of vaccine API (live, attenuated vaccine, recombinant vaccine, conjugate vaccine, inactivated vaccine, DNA vaccine, peptide vaccine, subunit vaccine, mRNA vaccine, toxoid vaccine and others), dosage form (ready to use liquid, lyophilized powder, nasal spray, capsule and tablet), dosage (single dose, 2 doses, 3 doses, 4 doses, 5 doses and 6 doses), target disease indication and target patient population (children, adults and seniors).

Chapter 5 features an insightful company competitiveness analysis of preventive vaccine developers based in North America, Europe and Asia Pacific. The analysis presents a comparison of the companies within each geography on the basis of supplier strength (based on company size and its experience in this field) and pipeline strength (based on number of clinical-stage vaccine candidates, highest phase of development, number of compatible routes of administration, number of indication evaluated, number of APIs evaluated and target patient population).

Chapter 6 provides elaborate profiles of the key preventive vaccine developers (shortlisted based on a proprietary criterion) across North America, Europe and Asia Pacific. Each profile includes a brief overview of the company, its year of establishment, location of headquarters, number of employees and financial information (if available). In addition to this, the profile includes information on the various clinical-stage vaccine candidates developed by the company. Further, we have provided the recent developments of the company and an informed future outlook.

Chapter 7 presents a detailed analysis of more than 1,400 completed, ongoing and planned clinical studies of preventive vaccines, highlighting prevalent trends across various relevant parameters, such as trial registration year, phase of development, trial recruitment status, study design, trial focus area, type of preventive vaccine (based on pathogen), target disease indication(s),  type of sponsor / collaborator, leading industry sponsors / collaborators (in terms of number of trials conducted), enrolled patients population and regional distribution.

Chapter 8 provides an overview of the ongoing vaccine development initiatives for complex conditions, such as COVID-19, ebola virus disease, HIV/AIDS, malaria and zika virus infection, including information on disease, its global burden, current treatment landscape and preventive vaccine research landscape. Further, we have provided the information on investments made and recent developments in the domain.

Chapter 9 presents an analysis of the investments made in this domain, during the period between 2015 and 2020 (till March), including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of development in companies that are engaged in developing preventive vaccines. 

Chapter 10 features a comprehensive market forecast, highlighting the future potential of this market till 2030 based on several parameters, such as target consumer segments, region specific adoption rates and expected prices of such products, we have provided an informed estimate on the likely evolution of the market over the period 2020-2030. The report also provides details on the likely distribution of the current and forecasted opportunity across [A] route of administration (intramuscular, subcutaneous, oral, intranasal, intradermal and others), [B] type of vaccine (pneumococcal conjugate vaccine, human papilloma virus vaccine, influenza vaccine, rotavirus vaccine, varicella vaccine, DTP-HepB-Hib vaccine, meningococcal group A, C, Y and W-135 vaccine and Other), [C] type of API (live attenuated vaccine, inactivated vaccine, conjugate vaccine, subunit vaccine, toxoid vaccine and others), [D] target patient population (pediatric and adults) and [E] key geographical regions, covering North America (the US, Mexico and Canada), Europe (Spain, the UK, Italy, France, Germany and rest of Europe), Asia Pacific (India, China, Australia and rest of Asia Pacific), and rest of the world. 

Chapter 11 presents a case study on contract manufacturing landscape for vaccines, featuring a comprehensive list of active CMOs and analyses based on a number of parameters, such as year of establishment, company size, scale of operation (preclinical, clinical and commercial), geographical location, number of vaccine manufacturing facilities, types of services offered (cell / virus banking, analytical development / testing, formulation, process development, fill / finish and regulatory filings), type of expression systems used for vaccine production (mammalian, microbial and others) and type of vaccine manufactured.

Chapter 12 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 13 is a collection of interview transcripts of discussions held with key stakeholder(s) in this market. 

Chapter 14 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 15 is an appendix, which contains the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Preventive Vaccines
3.2.1. Classification of Vaccines
3.2.1.1. Live, Attenuated Vaccines
3.2.1.2. Inactivated Vaccines
3.2.1.3. Subunit Vaccines
3.2.1.4. Toxoid Vaccines
3.2.1.5. DNA Vaccines

3.2.2. Key Components of a Vaccine Formulation
3.2.3. Production of Vaccines using Different Expression Systems
3.2.3.1. Embryonated Chicken Eggs and Primary Chicken Embryonic Fibroblasts (CEFs)
3.2.3.2. Mammalian Expression Systems
3.2.3.3. Avian Expression Systems
3.2.3.4. Plant Expression Systems
3.2.3.5. Bacterial Expression Systems
3.2.3.6. Yeast Expression Systems
3.2.3.7. Insect Expression System

3.2.4. Routes of Vaccine Administration
3.2.4.1. Intramuscular Route
3.2.4.2. Subcutaneous Route
3.2.4.3. Oral Route
3.2.4.4. Intranasal Route
3.2.4.5. Intradermal Route
3.2.4.6. Inhalation

3.2.5. Clinical Development and Approval of Vaccines
3.2.6. Future Perspectives

4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Preventive Vaccines: Overall Market Landscape
4.2.1. Marketed Vaccines Landscape
4.2.2. Clinical-Stage Vaccines Landscape
4.2.2.1. Analysis by Type of Developer
4.2.2.2. Analysis by Phase of Development
4.2.2.3. Analysis by Route of Administration
4.2.2.4. Analysis by Type of Vaccine API
4.2.2.5. Analysis by Dosage Form
4.2.2.6. Analysis by Dosage
4.2.2.7. Analysis by Target Disease Indication
4.2.2.8. Analysis by Target Patient Population
4.2.2.9. Key Industry Players: Analysis by Number of Vaccines in Clinical Development
4.2.2.10. Key Non-Industry Players: Analysis by Number of Vaccines in Clinical Development

5. COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Methodology
5.3. Assumptions and Key Parameters
5.4. Competitiveness Analysis: Preventive Vaccine Developers
5.4.1. Preventive Vaccine Developers based in North America
5.4.2. Preventive Vaccine Developers based in Europe
5.4.3. Preventive Vaccine Developers based in Asia Pacific

6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Bio Farma
6.2.1. Company Overview
6.2.2. Preventive Vaccines Portfolio
6.2.3. Recent Developments and Future Outlook

6.3. Emergent BioSolutions
6.3.1. Company Overview
6.3.2. Preventive Vaccines Portfolio
6.3.3. Recent Developments and Future Outlook

6.4. GC Pharma
6.4.1. Company Overview
6.4.2. Preventive Vaccines Portfolio
6.4.3. Recent Developments and Future Outlook

6.5. GlaxoSmithKline
6.5.1. Company Overview
6.5.2. Preventive Vaccines Portfolio
6.5.3. Recent Developments and Future Outlook

6.6. Janssen
6.6.1. Company Overview
6.6.2. Preventive Vaccines Portfolio
6.6.3. Recent Developments and Future Outlook

6.7. Merck
6.7.1. Company Overview
6.7.2. Preventive Vaccines Portfolio
6.7.3. Recent Developments and Future Outlook

6.8. Novavax
6.8.1. Company Overview
6.8.2. Preventive Vaccines Portfolio
6.8.3. Recent Developments and Future Outlook

6.9. Pfizer
6.9.1. Company Overview
6.9.2. Preventive Vaccines Portfolio
6.9.3. Recent Developments and Future Outlook

6.10. Sanofi Pasteur
6.10.1. Company Overview
6.10.2. Preventive Vaccines Portfolio
6.10.3. Recent Developments and Future Outlook

6.11. Valneva
6.11.1. Company Overview
6.11.2. Preventive Vaccines Portfolio
6.11.3. Recent Developments and Future Outlook

7. CLINICAL TRIAL ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Preventive Vaccines: Clinical Trial Analysis
7.3.1. Analysis by Trial Registration Year
7.3.2. Analysis by Enrolled Patient Population and Trial Registration Year
7.3.3. Analysis by Trial Phase
7.3.4. Analysis by Trial Recruitment Status
7.3.5. Analysis by Study Design
7.3.6. Analysis by Trial Focus Area
7.3.7. Analysis by Type of Preventive Vaccine (based on Pathogen)
7.3.8. Analysis by Target Disease Indication
7.3.9. Analysis by Type of Sponsor / Collaborator
7.3.10. Leading Industry Players: Analysis by Number of Registered Trials
7.3.11. Geographical Analysis by Number of Registered Trials
7.3.12. Geographical Analysis by Enrolled Patient Population
7.3.13. Geographical Analysis by Trial Recruitment Status

8. ONGOING VACCINE DEVELOPMENT INITIATIVES FOR COMPLEX CONDITIONS
8.1. Chapter Overview
8.2. Coronavirus Disease (COVID-19)
8.2.1. Disease Overview
8.2.2. Global Burden of COVID-19
8.2.3. Current Treatment Landscape
8.2.4. Preventive Vaccines for COVID-19
8.2.4.1. Historical Background of COVID-19 Vaccine Research
8.2.4.2. COVID-19 and Affiliated Research Landscape
8.2.5. Funding Instances
8.2.6. Recent Developments

8.3. Ebola Virus Disease (EVD)
8.3.1. Disease Overview
8.3.2. Global Burden of EVD
8.3.3. Current Treatment Landscape
8.3.4. Preventive Vaccines for EVD
8.3.4.1. Historical Background of Ebola Virus Vaccine Research
8.3.4.2. Anti-Ebola Virus Vaccines and Affiliated Research Landscape
8.3.5. Funding Instances
8.3.6. Recent Developments

8.4. HIV/AIDS
8.4.1. Disease Overview
8.4.2. Global Burden of HIV/AIDS
8.4.3. Current Treatment Landscape
8.4.4. Preventive Vaccines for HIV/AIDS
8.4.4.1. Historical Background of HIV/AIDS Vaccine Research
8.4.4.2. Anti-HIV Vaccines and Affiliated Research Landscape
8.4.5. Funding Instances
8.4.6. Recent Developments

8.5. Malaria
8.5.1. Disease Overview
8.5.2. Global Burden of Malaria
8.5.3. Current Treatment Landscape
8.5.4. Preventive Vaccines for Malaria
8.5.4.1. Historical Background of Malaria Vaccine Research
8.5.4.2. Anti-Malaria Vaccines and Affiliated Research Landscape
8.5.5. Funding Instances
8.5.6. Recent Developments

8.6. Zika Virus Infection
8.6.1. Disease Overview
8.6.2. Global Burden of Zika Virus Infection
8.6.3. Current Treatment Landscape
8.6.4. Preventive Vaccines for Zika Virus Infection
8.6.4.1. Historical Background of Zika Virus Vaccine Research
8.6.4.2. Anti-Zika Virus Vaccines and Affiliated Research Landscape
8.6.5. Funding Instances
8.6.6. Recent Developments

9. FUNDING AND INVESTMENT ANALYSIS
9.1. Chapter Overview
9.2. Types of Funding
9.3. Preventive Vaccines: Funding and Investment Analysis
9.3.1. Analysis by Number of Funding Instances
9.3.2. Analysis by Amount Invested
9.3.3. Analysis by Type of Funding
9.3.4. Analysis by Amount Invested across Different Types of Vaccine API
9.3.5. Analysis by Focus Area
9.3.6. Analysis by Amount Invested by Different Type of Investors
9.3.7. Most Active Players: Analysis by Number of Funding Instances
9.3.8. Most Active Investors: Analysis by Number of Funding Instances
9.3.9. Analysis by Geography
9.3.9.1. Continent-wise Analysis
9.3.9.2. Country-wise Analysis

10. MARKET SIZING AND OPPORTUNITY ANALYSIS
10.1. Chapter Overview
10.2. Forecast Methodology and Key Assumptions
10.3. Overall Preventive Vaccines Market, 2020-2030
10.3.1. Preventive Vaccines Market, 2020-2030: Distribution by Route of Administration
10.3.2. Preventive Vaccines Market, 2020-2030: Distribution by Type of Vaccine
10.3.3. Preventive Vaccines Market, 2020-2030: Distribution by Type of Vaccine API
10.3.4. Preventive Vaccines Market, 2020-2030: Distribution by Target Patient Population
10.3.5. Preventive Vaccines Market, 2020-2030: Distribution by Key Geographical Regions
10.3.5.1. Preventive Vaccines Market in North America, 2020-2030
10.3.5.1.1. Preventive Vaccines Market in the US, 2020-2030
10.3.5.1.2. Preventive Vaccines Market in Mexico, 2020-2030
10.3.5.1.2. Preventive Vaccines Market in Canada, 2020-2030

10.3.5.2. Preventive Vaccines Market in Europe, 2020-2030
10.3.5.2.1. Preventive Vaccines Market in Spain, 2020-2030
10.3.5.2.2. Preventive Vaccines Market in the UK, 2020-2030
10.3.5.2.3. Preventive Vaccines Market in Italy, 2020-2030
10.3.5.2.4. Preventive Vaccines Market in France, 2020-2030
10.3.5.2.5. Preventive Vaccines Market in Germany, 2020-2030
10.3.5.2.6. Preventive Vaccines Market in Rest of Europe, 2020-2030

10.3.5.3. Preventive Vaccines Market in Asia Pacific, 2020-2030
10.3.5.3.1. Preventive Vaccines Market in India, 2020-2030
10.3.5.3.2. Preventive Vaccines Market in China, 2020-2030
10.3.5.3.3. Preventive Vaccines Market in Australia, 2020-2030
10.3.5.3.4. Preventive Vaccines Market in Rest of Asia Pacific, 2020-2030

10.3.5.4. Preventive Vaccines Market in Rest of the World, 2020-2030
 
11. CASE-IN-POINT: CONTRACT MANUFACTURING OF VACCINES
11.1. Chapter Overview
11.2. Vaccine Contract Manufacturing
11.2.1. Addressing an Unmet Need
11.2.2. Commonly Outsourced Operations
11.2.3. Selecting a CMO Partner
11.2.4. Advantages of Outsourcing Manufacturing Services
11.2.5. Associated Risks and Challenges

11.3. Vaccine Contract Manufacturing: Overall Market Landscape
11.3.1. Analysis by Year of Establishment
11.3.2. Analysis by Company Size
11.3.3. Analysis by Scale of Operation
11.3.4. Analysis by Location of Headquarters
11.3.5. Analysis by Location of Manufacturing Facilities
11.3.6. Analysis by Type of Service(s) Offered
11.3.7. Analysis by Expression System Used
11.3.8. Analysis by Type of Vaccine Manufactured
11.3.9. Analysis by Type of Vaccine Manufactured and Location of Headquarters

12. CONCLUDING REMARKS

13. EXECUTIVE INSIGHTS
13.1. Chapter Overview

13.2. Alopexx
13.2.1. Company Snapshot
13.2.2. Interview Transcript: Daniel R. Vlock, Chief Executive Officer

14. APPENDIX 1: TABULATED DATA

15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 Difference Between Vaccines and Small Molecules
Figure 3.2 Classification of Vaccines
Figure 3.3 Routes for Vaccine Administration
Figure 4.1 Clinical-Stage Preventive Vaccines: Distribution by Type of Developer
Figure 4.2 Clinical-Stage Preventive Vaccines: Distribution by Phase of Development
Figure 4.3 Clinical-Stage Preventive Vaccines: Distribution by Route of Administration
Figure 4.4 Clinical-Stage Preventive Vaccines: Distribution by Type of Vaccine API
Figure 4.5 Clinical-Stage Preventive Vaccines: Distribution by Type of Vaccine API and Phase of Development
Figure 4.6 Clinical-Stage Preventive Vaccines: Distribution by Dosage Form
Figure 4.7 Clinical-Stage Preventive Vaccines: Distribution by Dosage
Figure 4.8 Clinical-Stage Preventive Vaccines: Distribution by Target Disease Indication
Figure 4.9 Clinical-Stage Preventive Vaccines: Distribution by Target Patient Population
Figure 4.10 Key Industry Players: Distribution by Number of Vaccines in Clinical Development
Figure 4.11 Key Non-Industry Players: Distribution by Number of Vaccines in Clinical Development
Figure 5.1 Company Competitiveness Analysis: Preventive Vaccine Developers based in North America
Figure 5.2 Company Competitiveness Analysis: Preventive Vaccine Developers based in Europe
Figure 5.3 Company Competitiveness Analysis: Preventive Vaccine Developers based in Asia Pacific
Figure 7.1 Clinical Trial Analysis: Scope and Methodology
Figure 7.2 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2010-2020
Figure 7.3 Clinical Trial Analysis: Distribution by Number of Patients Enrolled by Trial Registration Year, Pre-2010-2020
Figure 7.4 Clinical Trial Analysis: Distribution by Trial Phase
Figure 7.5 Clinical Trial Analysis: Distribution by Trial Recruitment Status
Figure 7.6 Clinical Trial Analysis: Cumulative Year-wise Trend by Trial Recruitment Status
Figure 7.7 Clinical Trial Analysis: Distribution by Study Design
Figure 7.8 Clinical Trial Analysis: Distribution by Trial Focus Area
Figure 7.9 Clinical Trial Analysis: Distribution by Type of Preventive Vaccine (based on Pathogen)
Figure 7.10 Clinical Trial Analysis: Cumulative Year-wise Trend by Type of Preventive Vaccines
Figure 7.11 Clinical Trial Analysis: Distribution by Target Disease Indication
Figure 7.12 Clinical Trial Analysis: Distribution by Patient Enrollment and Target Disease Indication
Figure 7.13 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 7.14 Leading Industry Players: Distribution by Number of Registered Trials
Figure 7.15 Clinical Trial Analysis: Geographical Distribution by Number of Registered Trials
Figure 7.16 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population
Figure 7.17 Clinical Trial Analysis: Geographical Distribution by Trial Registration Year and Recruitment Status
Figure 8.1 Historical Timeline of COVID-19 Vaccine Development
Figure 8.2 Historical Timeline of Anti-Ebola Virus Vaccine Development
Figure 8.3 Historical Timeline of Anti-HIV Vaccine Development
Figure 8.4 Historical Timeline of Anti-Malaria Vaccine Development
Figure 8.5 Historical Timeline of Anti-Zika Virus Vaccine Development
Figure 9.1 Funding and Investment Analysis: Cumulative Number of Instances by Year, 2015-Q1 2020
Figure 9.2 Funding and Investment Analysis: Cumulative Amount Invested, 2015-Q1 2020 (USD Million)
Figure 9.3 Funding and Investment Analysis: Distribution by Type of Funding, 2015-Q1 2020
Figure 9.4 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding, 2015-Q1 2020 (USD Million)
Figure 9.5 Funding and Investment Analysis: Distribution of Amount Invested by Type of Vaccine API
Figure 9.6 Funding and Investment Analysis: Distribution of Amount Invested and Focus Area
Figure 9.7 Funding and Investment Analysis: Distribution of Amount Invested by Different Type of Investors
Figure 9.8 Most Active Players: Distribution by Number of Funding Instances
Figure 9.9 Most Active Investors: Distribution by Number of Funding Instances
Figure 9.10 Funding and Investment Analysis: Regional Distribution by Number of Funding Instances and Amount Raised (USD Million)
Figure 9.11 Funding and Investment Analysis: Country-wise Distribution by Total Amount Invested (USD Million)
Figure 10.1 Overall Preventive Vaccines Market, 2020-2030 (USD Billion)
Figure 10.2 Preventive Vaccines Market, 2020-2030: Distribution by Route of Administration (USD Billion)
Figure 10.3 Preventive Vaccines Market, 2020-2030: Distribution by Type of Vaccine (USD Billion)
Figure 10.4 Preventive Vaccines Market, 2020-2030: Distribution by Type of Vaccine API (USD Billion)
Figure 10.5 Preventive Vaccines Market, 2020-2030: Distribution by Target Patient Population (USD Billion)
Figure 10.6 Preventive Vaccines Market, 2020-2030: Distribution by Key Geographical Regions (USD Billion)
Figure 10.7 Preventive Vaccines Market in North America, 2020-2030 (USD Billion)
Figure 10.8 Preventive Vaccines Market in the US, 2020-2030 (USD Billion)
Figure 10.9 Preventive Vaccines Market in Mexico, 2020-2030 (USD Billion)
Figure 10.10 Preventive Vaccines Market in Canada, 2020-2030 (USD Billion)
Figure 10.11 Preventive Vaccines Market in Europe, 2020-2030 (USD Billion)
Figure 10.12 Preventive Vaccines Market in Spain, 2020-2030 (USD Billion)
Figure 10.13 Preventive Vaccines Market in the UK, 2020-2030 (USD Billion)
Figure 10.14 Preventive Vaccines Market in Italy, 2020-2030 (USD Billion)
Figure 10.15 Preventive Vaccines Market in France, 2020-2030 (USD Billion)
Figure 10.16 Preventive Vaccines Market in Germany, 2020-2030 (USD Billion)
Figure 10.17 Preventive Vaccines Market in Rest of Europe, 2020-2030 (USD Billion)
Figure 10.18 Preventive Vaccines Market in Asia Pacific, 2020-2030 (USD Billion)
Figure 10.19 Preventive Vaccines Market in India, 2020-2030 (USD Billion)
Figure 10.20 Preventive Vaccines Market in China, 2020-2030 (USD Billion)
Figure 10.21 Preventive Vaccines Market in Australia, 2020-2030 (USD Billion)
Figure 10.22 Preventive Vaccines Market in Rest of Asia Pacific, 2020-2030 (USD Billion)
Figure 10.23 Preventive Vaccines Market in Rest of the World, 2020-2030 (USD Billion)
Figure 11.1 Type of Third-Party Service Providers in the Pharmaceutical Industry
Figure 11.2 Commonly Outsourced Vaccine Development Operations
Figure 11.3 Key Factors to Consider while Selecting a CMO Partner
Figure 11.4 Risks and Challenges Associated with Contract Manufacturing
Figure 11.5 Vaccine CMOs: Distribution by Year of Establishment
Figure 11.6 Vaccine CMOs: Distribution by Company Size
Figure 11.7 Vaccine CMOs: Distribution by Scale of Operation
Figure 11.8 Vaccine CMOs: Distribution by Location of Headquarters (Region and Country-wise)
Figure 11.9 Vaccine CMOs: Distribution by Location of Manufacturing Facility (Region-wise)
Figure 11.10 Vaccine CMOs: Distribution by Type of Services Offered
Figure 11.11 Vaccine CMOs: Distribution by Expression System Used
Figure 11.12 Vaccine CMOs: Distribution by Type of Vaccine Manufactured
Figure 11.13 Vaccine CMOs: Distribution by Type of Vaccine Manufactured and Location of Headquarters

List Of Tables

Table 3.1 Classification of Vaccines
Table 3.2 Live, Attenuated Vaccines: Commonly Reported Adverse Events
Table 3.3 Inactivated Vaccines: Commonly Reported Adverse Events
Table 3.4 Subunit Vaccines: Commonly Reported Adverse Events
Table 3.5 Toxoid Vaccines: Commonly Reported Adverse Events
Table 3.6 Vaccine Excipients and their Functions
Table 3.7 Routes of Administration and Type of Delivery Devices for Vaccine Administration
Table 3.8 Common Pediatric Vaccines and their Routes of Administration
Table 4.1 List of Marketed Preventive Vaccines
Table 4.2 List of Clinical-Stage Preventive Vaccines
Table 6.1 Preventive Vaccine Developers: List of Companies Profiled
Table 6.2 Bio Farma: Company Overview
Table 6.3 Bio Farma: Preventive Vaccine Pipeline
Table 6.4 Bio Farma: Recent Developments and Future Outlook
Table 6.5 Emergent BioSolutions: Company Overview
Table 6.6 Emergent BioSolutions: Preventive Vaccine Pipeline
Table 6.7 Emergent BioSolutions: Recent Developments and Future Outlook
Table 6.8 GC Pharma: Company Overview
Table 6.9 GC Pharma: Preventive Vaccine Pipeline
Table 6.10 GC Pharma: Recent Developments and Future Outlook
Table 6.11 GlaxoSmithKline: Company Overview
Table 6.12 GlaxoSmithKline: Preventive Vaccine Pipeline
Table 6.13 GlaxoSmithKline: Recent Developments and Future Outlook
Table 6.14 Janssen: Company Overview
Table 6.15 Janssen: Preventive Vaccine Pipeline
Table 6.16 Janssen: Recent Developments and Future Outlook
Table 6.17 Merck: Company Overview
Table 6.18 Merck: Preventive Vaccine Pipeline
Table 6.19 Merck: Recent Developments and Future Outlook
Table 6.20 Novavax: Company Overview
Table 6.21 Novavax: Preventive Vaccine Pipeline
Table 6.22 Novavax: Recent Developments and Future Outlook
Table 6.23 Pfizer: Company Overview
Table 6.24 Pfizer: Preventive Vaccine Pipeline
Table 6.25 Pfizer: Recent Developments and Future Outlook
Table 6.26 Sanofi Pasteur: Company Overview
Table 6.27 Sanofi Pasteur: Preventive Vaccine Pipeline
Table 6.28 Sanofi Pasteur: Recent Developments and Future Outlook
Table 6.29 Valneva: Company Overview
Table 6.30 Valneva: Preventive Vaccine Pipeline
Table 6.31 Valneva: Recent Developments and Future Outlook
Table 8.1 Preventive Vaccines under Investigation for COVID-19
Table 8.2 COVID-19 Vaccines: Funding Instances
Table 8.3 Ebola Virus Disease: List of Marketed Therapeutics
Table 8.4 Preventive Vaccines under Investigation for Ebola Virus Disease
Table 8.5 Anti-Ebola Virus Vaccines: Funding Instances
Table 8.6 HIV/AIDS: List of Marketed Therapeutics
Table 8.7 Preventive Vaccines under Investigation for HIV/AIDS
Table 8.8 Anti-HIV Vaccines: Funding Instances
Table 8.9 Malaria: List of Marketed Therapeutics
Table 8.10 Preventive Vaccines under Investigation for Malaria
Table 8.11 Anti-Malaria Vaccines: Funding Instances
Table 8.12 Preventive Vaccines under Investigation for Zika Virus Infection
Table 8.13 Anti-Zika Virus Vaccines: Funding Instances
Table 9.1 Preventive Vaccines: List of Funding and Investments, till Q1 2020
Table 11.1 Vaccine Contract Manufacturers: List of Service Providers
Table 11.2 Vaccine CMOs: Information on Type of Services Offered
Table 11.3 Vaccine CMOs: Information on Scale of Operation
Table 11.4 Vaccine CMOs: Information on Expression System Used
Table 11.5 Vaccine CMOs: Information on Type of Vaccines Manufactured
Table 11.6 List of Ad hoc Vaccine Manufacturers
Table 12.1 Preventive Vaccines Market: Summary of the Report
Table 14.1 Clinical-Stage Preventive Vaccines: Distribution by Type of Developer
Table 14.2 Clinical-Stage Preventive Vaccines: Distribution by Phase of Development
Table 14.3 Clinical-Stage Preventive Vaccines: Distribution by Route of Administration
Table 14.4 Clinical-Stage Preventive Vaccines: Distribution by Type of Vaccine API
Table 14.5 Clinical-Stage Preventive Vaccines: Distribution by Type of Vaccine API and Phase of Development
Table 14.6 Clinical-Stage Preventive Vaccines: Distribution by Dosage Form
Table 14.7 Clinical-Stage Preventive Vaccines: Distribution by Dosage
Table 14.8 Clinical-Stage Preventive Vaccines: Distribution by Target Disease Indication
Table 14.9 Clinical-Stage Preventive Vaccines: Distribution by Target Patient Population
Table 14.10 Key Industry Players: Distribution by Number of Vaccines in Clinical Development
Table 14.11 Key Non-Industry Players: Distribution by Number of Vaccines in Clinical Development
Table 14.12 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2010-2020
Table 14.13 Clinical Trial Analysis: Distribution by Number of Patients Enrolled by Trial Registration Year, Pre-2010-2020
Table 14.14 Clinical Trial Analysis: Distribution by Trial Phase
Table 14.15 Clinical Trial Analysis: Distribution by Trial Recruitment Status
Table 14.16 Clinical Trial Analysis: Cumulative Year-wise Trend by Trial Recruitment Status
Table 14.17 Clinical Trial Analysis: Distribution by Study Design
Table 14.18 Clinical Trial Analysis: Distribution by Trial Focus Area
Table 14.19 Clinical Trial Analysis: Distribution by Type of Preventive Vaccine (based on Pathogen)
Table 14.20 Clinical Trial Analysis: Cumulative Year-wise Trend by Type of Preventive Vaccines
Table 14.21 Clinical Trial Analysis: Distribution by Target Disease Indication
Table 14.22 Clinical Trial Analysis: Distribution by Patient Enrollment and Target Disease Indication
Table 14.23 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 14.24 Leading Industry Players: Distribution by Number of Registered Trials
Table 14.25 Funding and Investment Analysis: Cumulative Number of Instances by Year, 2015-Q1 2020
Table 14.26 Funding and Investment Analysis: Cumulative Amount Invested, 2015-Q1 2020 (USD Million)
Table 14.27 Funding and Investment Analysis: Distribution by Type of Funding, 2015-Q1 2020
Table 14.28 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding, 2015-Q1 2020 (USD Million)
Table 14.29 Funding and Investment Analysis: Distribution of Amount Invested by Type of Vaccine API
Table 14.30 Funding and Investment Analysis: Distribution of Amount Invested by Focus Area
Table 14.31 Funding and Investment Analysis: Distribution of Amount Invested by Different Type of Investors
Table 14.32 Most Active Players: Distribution by Number of Funding Instances
Table 14.33 Most Active Investors: Distribution by Number of Funding Instances
Table 14.34 Funding and Investment Analysis: Regional Distribution by Number of Funding Instances and Amount Raised (USD Million)
Table 14.35 Funding and Investment Analysis: Country-wise Distribution by Total Amount Invested (USD Million)
Table 14.36 Overall Preventive Vaccines Market, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 14.37 Preventive Vaccines Market, 2020-2030: Distribution by Route of Administration (USD Billion)
Table 14.38 Preventive Vaccines Market, 2020-2030: Distribution by Type of Vaccine (USD Billion)
Table 14.39 Preventive Vaccines Market, 2020-2030: Distribution by Type of Vaccine API (USD Billion)
Table 14.40 Preventive Vaccines Market, 2020-2030: Distribution by Target Patient Population (USD Billion)
Table 14.41 Preventive Vaccines Market, 2020-2030: Distribution by Key Geographical Regions (USD Billion)
Table 14.42 Preventive Vaccines Market in North America, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 14.43 Preventive Vaccines Market in the US, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 14.44 Preventive Vaccines Market in Mexico, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 14.45 Preventive Vaccines Market in Canada, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 14.46 Preventive Vaccines Market in Europe, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 14.47 Preventive Vaccines Market in Spain, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 14.48 Preventive Vaccines Market in the UK, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 14.49 Preventive Vaccines Market in Italy, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 14.50 Preventive Vaccines Market in France, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 14.51 Preventive Vaccines Market in Germany, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 14.52 Preventive Vaccines Market in Rest of Europe, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 14.53 Preventive Vaccines Market in Asia Pacific, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 14.54 Preventive Vaccines Market in India, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 14.55 Preventive Vaccines Market in China, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 14.56 Preventive Vaccines Market in Australia, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 14.57 Preventive Vaccines Market in Rest of Asia Pacific, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 14.58 Preventive Vaccines Market in Rest of the World, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 14.59 Vaccine CMOs: Distribution by Year of Establishment
Table 14.60 Vaccine CMOs: Distribution by Company Size
Table 14.61 Vaccine CMOs: Distribution by Scale of Operation
Table 14.62 Vaccine CMOs: Distribution by Location of Headquarters (Region and Country-wise)
Table 14.63 Vaccine CMOs: Distribution by Location of Manufacturing Facility (Region-wise)
Table 14.64 Vaccine CMOs: Distribution by Type of Services Offered
Table 14.65 Vaccine CMOs: Distribution by Expression System Used
Table 14.66 Vaccine CMOs: Distribution by Type of Vaccines Manufactured
Table 14.67 Vaccine CMOs: Region-wise Distribution by Type of Vaccine Manufactured

Listed Companies

The following companies and organizations have been mentioned in the report.

  1. 3P Biopharmaceuticals
  2. Abbott Biologicals
  3. AbbVie Contract Manufacturing
  4. Aberdeen Proving Ground
  5. ABL
  6. Abu Dhabi Investment Authority
  7. Abzena
  8. Adimmune 
  9. Adjuvant Capital
  10. Advagene Biopharma
  11. Affinivax
  12. AJ Biologics
  13. AJ Vaccines
  14. Ajinomoto Bio-Pharma Services
  15. Alexandria Venture Investments
  16. Alopexx Vaccine
  17. Altimmune
  18. AmbioPharm
  19. AMRI
  20. Anaxago
  21. Angels High Tech Investments
  22. Anhui Zhifei Longcom Biologic Pharmacy
  23. ARCH Venture Partners
  24. ArrowMark Partners
  25. Astellas Pharma
  26. Atlantic Methanol Production Company
  27. Auro Vaccines
  28. Avid Bioservices
  29. AVIR Green Hills Biotechnology
  30. aws Gründerfonds
  31. Barr Laboratories
  32. Batavia Biosciences
  33. Bavarian Nordic
  34. Baxter BioPharma Solutions
  35. Baylor College of Medicine
  36. BB Biotech
  37. Beijing Center for Disease Control and Prevention
  38. Beijing Institute of Biological Products
  39. Beijing Minhai Biotechnology
  40. Beijing Zhifei Lvzhu Biopharmaceutical
  41. Bharat Biotech
  42. Bharat Serums and Vaccine
  43. Bill & Melinda Gates Foundation
  44. Bilthoven Biologicals
  45. BINEX
  46. Bio Elpida
  47. Bio Farma
  48. BioCell
  49. BioConnections
  50. Biofabri
  51. Biological E.
  52. Bio-Manguinhos
  53. BioMARC
  54. Biomay
  55. Biomedical Advanced Research and Development Authority
  56. BioMedPartners
  57. BiondVax Pharmaceuticals
  58. BioReliance
  59. BioTechLogic
  60. BioTechnique
  61. BlueWillow Biologics
  62. Boehringer Ingelheim BioXcellence
  63. Boehringer Ingelheim Venture Fund
  64. Boryung Pharmaceutical
  65. Brammer Bio
  66. Bryllan
  67. Bul Bio-National Center of Infectious and Parasitic Diseases
  68. Burrard Pharmaceuticals
  69. Cadila Healthcare
  70. CanSino Biologics
  71. CARBOGEN AMCIS
  72. CARB-X
  73. Catalent
  74. Center for Genetic Engineering and Biotechnology
  75. Century Pharmaceuticals
  76. CEPI
  77. Cerberus Capital Management
  78. CEVEC Pharmaceuticals
  79. Charles River Laboratories
  80. Chengdu Institute of Biological Products 
  81. Chiron Behring Vaccines
  82. Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences
  83. CJ HealthCare
  84. Cobra Biologics
  85. Codagenix
  86. Consort Medical
  87. CRG
  88. CSL
  89. CureVac
  90. Curevo
  91. Cytovance Biologics
  92. Dalton Pharma Services
  93. Danish Government
  94. Danish Innovation Foundation
  95. Dartmouth-Hitchcock Medical Center
  96. Deerfield Management
  97. Department of the Army
  98. Division of AIDS
  99. Duke Human Vaccine Institute
  100. Dynavax Technologies
  101. EDBI
  102. EirGenix
  103. Emergent BioSolutions
  104. Emergent Product Development Gaithersburg
  105. Emergex Vaccines
  106. Ethiopian Government 
  107. EuBiologics
  108. Euclidean Capital
  109. Eurofins Amatsigroup
  110. Eurogentec
  111. EDCTP
  112. European Investment Bank
  113. European Union
  114. Eveliqure Biotechnologies
  115. Farallon Capital
  116. Federal State Budgetary Scientific Institution
  117. FF DSF VI
  118. Fidelity Investments
  119. Fiocruz
  120. FluGen
  121. Forbion
  122. Fort Detrick
  123. Fortune Capital
  124. FUJIFILM Diosynth Biotechnologies
  125. FundRx
  126. Future Industry Investment Fund
  127. Gamaleya Research Institute of Epidemiology and Microbiology
  128. GC Cell
  129. GC Pharma
  130. GeneMatrix
  131. GeneOne Life Science
  132. GenIbet Biopharmaceuticals
  133. Georgia Institute of Technology
  134. Gilead
  135. GlaxoSmithKline
  136. Global Health Investment Fund
  137. Goldstone Investment
  138. Gopher Asset Management
  139. Government of the Republic of Equatorial Guinea
  140. Government of Norway
  141. GPO-MBP
  142. GreenPak Biotech
  143. GreenSignal Bio Pharma
  144. GTP Technology
  145. GV
  146. Hadean Ventures
  147. Haffkine Bio-Pharmaceutical
  148. HALIX
  149. Hawaii Biotech
  150. HBM Partners
  151. Health Biotech
  152. HealthCap
  153. Hillhouse Capital
  154. Hong Kong Institute of Biotechnology
  155. HOOKIPA Pharma
  156. Hualan Biological Bacterin
  157. Icahn School of Medicine at Mount Sinai
  158. IDT Biologika
  159. ILiAD Biotechnologies
  160. Il-Yang Pharmaceutical
  161. Immunobiological Technology Institute (BioManguinhos)
  162. Imperial College London
  163. Indian Immunologicals
  164. Infectious Disease Research Institute
  165. Innovate UK
  166. Inovio Pharmaceuticals
  167. Institut Pasteur de Dakar
  168. Institute for Biomedical Science
  169. Institute of Vaccines and Medical Biologicals
  170. Instituto Nacional de Saúde
  171. Intas
  172. Integrity Bio
  173. International AIDS Vaccine Initiative
  174. International Centre for Diarrhoeal Disease Research, Bangladesh
  175. International Vaccine Institute
  176. Invus
  177. Israel Innovation Authority
  178. Israel Investment Center
  179. Jack Ma Foundation
  180. Janssen
  181. Japan Bank for International Cooperation
  182. Japan BCG Laboratory
  183. JEMS Venture Capital
  184. Jiangsu Provincial Center for Disease Control and Prevention
  185. JN-International Medical
  186. Johnson & Johnson Innovation
  187. Joint Program Executive Office for Chemical and Biological Defense
  188. JSR
  189. Jubilant HollisterStier
  190. Julius Baer
  191. Kemwell Biopharma
  192. King Abdullah International Medical Research Center
  193. Knox
  194. Korea Investment Partners
  195. LF Investment
  196. LG Chem
  197. Lilly Asia Ventures
  198. LimmaTech Biologics
  199. Line Moon Ventures
  200. Liontrust
  201. Lonza
  202. LuinaBio
  203. Mahidol University
  204. Marathon Oil Corporation
  205. Massachusetts General Hospital
  206. MassBiologics
  207. MCM Vaccine
  208. Ministry of Health of the Russian Federation
  209. Medicago
  210. Medical Countermeasure Systems–Joint Vaccine Acquisition Program
  211. Medigen Vaccine Biologics
  212. MedImmune
  213. Meissa Vaccines
  214. Merck
  215. Meridian Life Science
  216. MIKROGEN 
  217. MinervaX
  218. Ministry of Economic Affairs
  219. Ministry of Foreign Affairs (Netherlands)
  220. Moderna
  221. Morningside Ventures
  222. MRC/UVRI Uganda Research Unit on AIDS
  223. MSD Wellcome Trust Hilleman Laboratories
  224. Mymetics
  225. Natick Contracting Division
  226. National Authority for Technological Innovation
  227. National Institute of Allergy and Infectious Diseases
  228. National Institutes of Health
  229. National Vaccine & Serum Institute
  230. Network-1 Technologies
  231. Nitto Avecia Pharma Services
  232. Noble Energy
  233. North Coast Technology Investors
  234. Noshaq
  235. Nova Immunotherapeutics
  236. Novartis
  237. Novartis Venture Fund
  238. Novasep
  239. Novavax
  240. Novo Holdings
  241. Novo Seeds
  242. NPO Petrovax Pharm
  243. Omnes Capital
  244. OPKO Health
  245. OrbiMed
  246. Organon Teknika
  247. Osivax
  248. Oxford Sciences Innovation
  249. Panacea Biotec
  250. PATH
  251. Perceptive Advisors
  252. Pfizer
  253. Pfizer CentreOne
  254. Pictet
  255. Pierre Fabre
  256. Piramal Pharma Solutions
  257. PnuVax
  258. Polymun Scientific
  259. Porton Biopharma
  260. Premas Biotech
  261. ProBioGen
  262. Profectus BioSciences
  263. Protein Sciences
  264. PX’Therapeutics
  265. Qiming Venture Partners
  266. Redmile Group
  267. Redmont Capital
  268. Reliance Life Sciences
  269. Research Foundation for Microbial Diseases, Osaka University
  270. Richter-Helm Biologics
  271. Rommelag CMO
  272. RTW Investments
  273. Russian Academy of Sciences
  274. Sabin Vaccine Institute
  275. Samsara BioCapital
  276. Sanaria
  277. Sanofi Pasteur
  278. Scandinavian Biopharma
  279. Scripps Research Institute
  280. SDS Capital Partners
  281. Seedlings Life Science Ventures
  282. SEEK
  283. Seqirus
  284. Sequoia
  285. Sequoia China
  286. Serum Institute of India
  287. Shanghai Bovax Biotechnology
  288. Shantha Biotechnics
  289. Sinovac Biotech
  290. Sirona Capital
  291. SK Bioscience
  292. Sofinnova Partners
  293. State of Wisconsin Investment Board
  294. Sunstone Capital
  295. Sunstone Life Science Ventures
  296. Swissfillon
  297. Syngene
  298. Takeda
  299. Takeda Ventures
  300. Teva Pharmaceuticals
  301. Texas Biomedical Research Institute
  302. The Peter Doherty Institute for Infection and Immunity 
  303. The Wistar Institute
  304. Themis Bioscience
  305. Thermo Fisher Scientific
  306. Topspin Partners
  307. Truffle Capital
  308. UK Government
  309. UK Research and Innovation
  310. Univercells
  311. University Health Network
  312. University Medical Center Hamburg-Eppendorf
  313. University of Amsterdam
  314. University of Antwerp
  315. University of California
  316. University of Georgia
  317. University of Maryland
  318. University of Michigan
  319. University of Minnesota
  320. University of Oxford
  321. University of Washington
  322. US Agency for International Development
  323. US Army Contracting Command
  324. US Army Medical Research and Materiel Command
  325. US Centers for Disease Control and Prevention
  326. US Defense Advanced Research Projects Agency
  327. US Defense Threat Reduction Agency
  328. US Department of Agriculture
  329. US Department of Defense
  330. Vaccitech
  331. Valneva
  332. Vaxart
  333. Vaxine
  334. VaxNewMo
  335. Vaxxilon
  336. VBI Vaccines
  337. Ventech
  338. Venture Investors
  339. Vetter Pharma
  340. VGXI
  341. Vibalogics
  342. Vickers Venture Partners
  343. Viking Global Investors
  344. Wacker Biotech
  345. Waisman Biomanufacturing
  346. Wallace Pharmaceuticals
  347. Wellington Partners Life Sciences
  348. Wisconsin Alumni Research Foundation
  349. WuXi Biologics
  350. Wuxi Griffin
  351. Wyeth Pharmaceuticals
  352. Xiamen University
  353. X-Vax Technology

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 4,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com